139 related articles for article (PubMed ID: 16842440)
1. The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.
Hornberger J; Farci P; Prati D; Zeuzem S; Green J; Patel KK
J Viral Hepat; 2006 Jun; 13(6):377-86. PubMed ID: 16842440
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
[TBL] [Abstract][Full Text] [Related]
6. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
Gerkens S; Nechelput M; Annemans L; Peraux B; Beguin C; Horsmans Y
Acta Gastroenterol Belg; 2007; 70(2):177-87. PubMed ID: 17715631
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of peginterferon alpha-2a and peginterferon alpha-2b combination regimens in genotype-1 naive patients with chronic hepatitis C.
Gheorghe L; Baculea S
Hepatogastroenterology; 2010; 57(101):939-44. PubMed ID: 21033255
[TBL] [Abstract][Full Text] [Related]
9. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.
Siebert U; Sroczynski G; Aidelsburger P; Rossol S; Wasem J; Manns MP; McHutchison JG; Wong JB
Pharmacoeconomics; 2009; 27(4):341-54. PubMed ID: 19485429
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.
Siebert U; Sroczynski G; Rossol S; Wasem J; Ravens-Sieberer U; Kurth BM; Manns MP; McHutchison JG; Wong JB; ;
Gut; 2003 Mar; 52(3):425-32. PubMed ID: 12584228
[TBL] [Abstract][Full Text] [Related]
11. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
Visconti AJ; Doyle JS; Weir A; Shiell AM; Hellard ME
J Gastroenterol Hepatol; 2013 Apr; 28(4):707-16. PubMed ID: 23173753
[TBL] [Abstract][Full Text] [Related]
12. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C.
Gerkens S; Nechelput M; Annemans L; Peraux B; Mouchart M; Beguin C; Horsmans Y
J Viral Hepat; 2007 Aug; 14(8):523-36. PubMed ID: 17650286
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1.
García-Contreras F; Nevárez-Sida A; Constantino-Casas P; Abud-Bastida F; Garduño-Espinosa J
Arch Med Res; 2006 Jul; 37(5):663-73. PubMed ID: 16740439
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
Veenstra DL; Sullivan SD; Dusheiko GM; Jacobs M; Aledort JE; Lewis G; Patel KK
Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.
Arora S; O'Brien C; Zeuzem S; Shiffman ML; Diago M; Tran A; Pockros PJ; Reindollar RW; Gane E; Patel K; Wintfeld N; Green J
J Gastroenterol Hepatol; 2006 Feb; 21(2):406-12. PubMed ID: 16509866
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security.
Siebert U; Sroczynski G; ;
Int J Technol Assess Health Care; 2005; 21(1):55-65. PubMed ID: 15736515
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
Vanagas G; Padaiga Z; Mickevičienė A
Medicina (Kaunas); 2010; 46(12):835-42. PubMed ID: 21532288
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C.
Nakamura J; Kobayashi K; Toyabe S; Aoyagi Y; Akazawa K
Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):733-9. PubMed ID: 17700257
[TBL] [Abstract][Full Text] [Related]
20. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C.
Wong JB; Davis GL; McHutchison JG; Manns MP; Albrecht JK;
Am J Gastroenterol; 2003 Nov; 98(11):2354-62. PubMed ID: 14638334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
